Search Results
Your search for ASCO Post matches 17430 pages
Showing 8451 - 8500Al Identifies Features of Tumor Cells in High-Risk Ovarian Cancer
Scientists have developed a new test that scans the shapes of tumor cells to select women with especially aggressive ovarian cancer. A team at The Institute of Cancer Research (ICR), London, created an artificial intelligence (AI) tool that looks for clusters of cells within tumors with misshapen...
Role of Donor Race in Liver Transplant Outcomes in African American Patients With Hepatocellular Carcinoma
Among African American adults undergoing liver transplant to treat hepatocellular carcinoma, patients whose organ donor was also African American lived significantly longer than those with a racially unmatched donor, report authors of a new study using national data. Their findings were published...
FDA Pipeline: Designations for Treatments of Graft-vs-Host-Disease, Colorectal Cancer, Pancreatic Cancer, and More
The U.S. Food and Drug Administration (FDA) recently issued the following new designations and clearances: Fast Track Designation for Itolizumab for the Treatment of Acute Graft-vs-Host Disease The FDA granted Fast Track designation to itolizumab for the treatment of acute graft-vs-host ...
BRCA Exchange: Resource Aggregates Data on BRCA Variants
A global resource that includes data on thousands of inherited variants in the BRCA1 and BRCA2 genes is available to the public. The BRCA Exchange was created through the BRCA Challenge, a long-term demonstration project initiated by the Global Alliance for Genomics and...
Patient Navigation Program Reduces Time to Treatment in Patients With Cancer
Global Cancer Institute recently announced the results of its Patient Navigation Program in Mexico City. The average time to referral before the program’s inception was 5 months, but the implementation of patient navigators reduced that average to 7 days. These findings were published by ...
Study Finds Elevated Risk of MDS and AML After Chemotherapy for Most Solid Tumors
Findings from a new study by researchers at the National Cancer Institute (NCI) show that patients treated with chemotherapy for most solid tumors from 2000 to 2014 experienced an increased risk of therapy-related myelodysplastic syndrome/acute myeloid leukemia (MDS/AML). The study, which used U.S. ...
27% Drop in Overall U.S. Cancer Mortality Rate From 1991 to 2016
A steady 25-year decline has resulted in a 27% drop in the overall cancer death rate in the United States between 1991 and 2016. The data come from “Cancer Statistics, 2019,” the American Cancer Society’s annual report on cancer rates and trends. The report was published in CA: A...
Higher Incidence of Brain and CNS Tumors Among People Living in Appalachia
A recent study published by Ostrom et al in the Journal of Neuro-Oncology showed that compared to the rest of the United States, the Appalachian region has a 5% higher incidence of malignant primary brain tumors and other central nervous system (CNS) tumors, a higher mortality rate due to ...
Association Between Sun Exposure and BMI in the Development of Nonmelanoma Skin Cancer
Exposure to the sun, whether cumulative or intermittent, is a known risk factor for the development of nonmelanoma skin cancer (NMSC). Past studies have found that greater body mass index (BMI) actually lessens the risk of women developing NMSCs. With this in mind, researchers sought to determine...
Gleason 6 Score May Underestimate Prostate Cancer Mortality Risk in Black Men
Black men diagnosed with prostate cancer classified as low risk may actually have a more aggressive form of the disease that is more likely to be fatal than in nonblack men placed in the same prognostic category, according to results from a new study published as a research letter by Mahal et al in ...
2018 Young-Onset Colorectal Cancer Survey Report Covers Disease Stage at Diagnosis and More
Nearly three-quarters of patients with young-onset colorectal cancer are diagnosed with an advanced stage of the disease, a significantly higher percentage than has been reported for their more mature peers, according to a report from the Colorectal Cancer Alliance. The findings of...
Quality of Life and Patient- and Clinician-Reported Cumulative Toxicity
New research has found that quality of life for people with cancer is reduced by an accumulation of low-level toxicities just as much as it is from high-level adverse events. Additionally, patient-reported outcomes were more likely to reflect the impact on a patient’s physical well-being than ...
Negative Colonoscopy and Long-Term Risk of Colorectal Cancer
Ten years after a negative colonoscopy, patients who were rescreened for colorectal cancer had a lower risk of being diagnosed with and were less likely to die from colorectal cancer compared with those who did not undergo colorectal cancer screening, according to a study published by Lee et al...
New Study Examines Orphan Drug Exclusivity and Pricing
A new report commissioned by the National Organization for Rare Disorders (NORD) and published by the IQVIA Institute demonstrates that the 7-year market exclusivity granted to drugs designated under the Orphan Drug Act of 1983 for rare diseases is working as intended. In nearly every case, orphan...
Facing Death: Having the Difficult Conversation With Your Patients
Michael Becker, a former CEO for two biotechnology companies, discusses his terminal head and neck cancer diagnosis and his message for oncologists: be proactive and, at the appropriate time, talk with your patients about death and dying. For more information about Michael Becker’s blog and his HPV ...
FDA Expands Indication for Dasatinib to Pediatric Patients With Ph+ ALL in Combination With Chemotherapy
On January 2, the U.S. Food and Drug Administration (FDA) expanded the indication for dasatinib (Sprycel) tablets to include the treatment of pediatric patients 1 year of age and older with newly diagnosed Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL) in...
Association Between Systemic Lupus Erythematosus and Cancer Risk
New research published by Song et al in Arthritis Research & Therapy evaluated the link between lupus and cancer risk, supporting the data from earlier studies. The newer study indicates an association between systemic lupus erythematosus (SLE) and increased risk for several cancers (blood,...
Study Assesses Impact of Digital Mammography on Breast Cancer Detection and Recall Rates
The shift from film to digital mammography increased the detection of breast cancer overall in the United Kingdom—without increasing the recall rate—according to a study published by Blanks et al in Radiology. “Image quality with digital mammography is improved over that of...
Pilot Study of Intratumoral G100 in Merkel Cell Carcinoma
Multiple recent reports have addressed the activity of programmed cell death protein 1 (PD-1) inhibitors, such as pembrolizumab and avelumab, in Merkel cell carcinoma. However, approximately half of all patients who receive these agents do not maintain a persistent response. In an...
High Long-Term Risk of Solid Cancers in Survivors of Childhood Hodgkin Lymphoma
A new study may bolster existing evidence that survivors of childhood Hodgkin lymphoma face an elevated risk of developing various types of solid tumors many years later. The study showed that certain subgroups of patients have an especially high risk. Published by Holmqvist et al in the journal...
FDA Approves Ravulizumab-cwvz for Paroxysmal Nocturnal Hemoglobinuria
On December 21, 2018, the U.S. Food and Drug Administration (FDA) approved ravulizumab-cwvz (Ultomiris) for adult patients with paroxysmal nocturnal hemoglobinuria (PNH). PNH is a rare bone marrow failure disorder that manifests with hemolytic anemia, thrombosis, and peripheral blood cytopenias....
FDA Approves Tagraxofusp-ezrs for Blastic Plasmacytoid Dendritic Cell Neoplasm
On December 21, the U.S. Food and Drug Administration (FDA) approved tagraxofusp-erzs (Elzonris) infusion for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients aged 2 years and older. “Prior to [this] approval, there had been no...
Louis M. Weiner, MD, Named National Academy of Inventors Fellow
THE NATIONAL ACADEMY OF INVENTORS (NAI) has named Louis M. Weiner, MD, Director of the Georgetown Lombardi Comprehensive Cancer Center, to its 2018 class of fellows. According to the National Academy of Inventors, election to NAI Fellow status is the “highest professional distinction accorded to...
IASLC Announces Dave Mesko, MBA, as New Chief Executive
THE INTERNATIONAL Association for the Study of Lung Cancer (IASLC) has announced Dave Mesko, MBA, as its new Chief Executive Officer. Mr. Mesko replaces Fred R. Hirsch, MD, PhD, who left IASLC after his 5-year term ended on October 31, 2018. Mr. Mesko will be primarily responsible for the overall ...
I Welcome Being the Face of Multiple Myeloma
Thirteen years ago, at age 34, I was healthy and enjoying life. I went to the gym almost daily, and when I wasn’t at the gym, I was shooting hoops with my friends. During a gym workout while on a family vacation, I suddenly felt excruciating pain in my left shoulder and thought I must have strained ...
ASCO Remembers Charles A. Coltman, Jr, MD, FASCO, Cooperative Trial Pioneer and ASCO Past President
ASCO AND THE ONCOLOGY COMMUNITY mourn the loss of ASCO Past President and former SWOG leader Charles A. Coltman, Jr, MD, FASCO, President Emeritus, Cancer Therapy & Research Center, The University of Texas Health Science Center at San Antonio. Dr. Coltman died on November 28 at the age of 88....
For Maria Papaleontiou, MD, Research Holds the Key to Improving Care of Patients With Thyroid Cancer
Maria Papaleontiou, MD, whose research interests focus on the complex issues surrounding the management of thyroid cancer and thyroid disease in general, was born on Cyprus, a small island nestled in the azure waters of the Mediterranean Sea. She recently spoke with The ASCO Post about her life and ...
Anil K. Rustgi, MD, Named Director of Herbert Irving Comprehensive Cancer Center
ANIL K. RUSTGI, MD, has been named Director of the Herbert Irving Comprehensive Cancer Center at Columbia University Irving Medical Center and NewYork-Presbyterian/Columbia University Irving Medical Center. Pending approval of the university’s trustees, Dr. Rustgi will serve as Professor of...
Stories of the Scientists Behind Immunotherapy
As the field of immunotherapy accelerates, so does the literature reporting on the path ahead. One of the newer books on the topic is A Cure Within: Scientists Unleashing the Immune System to Kill Cancer. It has a top-notch pedigree: the author, Neil Canavan, is a seasoned journalist with more than ...
Breakthrough Therapy Designation for Brentuximab Vedotin in Front-Line Treatment of Peripheral T-Cell Lymphomas
THE FDA recently granted Breakthrough Therapy designation to brentuximab vedotin (Adcetris) for previously untreated systemic anaplastic large cell lymphoma or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in ...
Priority Review for Quizartinib in Relapsed or Refractory FLT3-ITD–Positive AML
THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) accepted a new drug application and granted Priority Review to quizartinib, a FLT3 inhibitor, for the treatment of adult patients with relapsed or refractory FLT3-ITD–positive acute myeloid leukemia (AML). The FDA is expected to make a decision on...
Welcome Questions About Cervical Cancer Treatment Options
TWO STUDIES reported in The New England Journal of Medicine1,2 showed that patients with early-stage cervical cancer had reduced disease-free and overall survival when treated with minimally invasive radical hysterectomy vs open or radical hysterectomy. The findings of these studies have been...
Comparing Survival Outcomes With Minimally Invasive and Open Surgical Approaches to Early-Stage Cervical Cancer
MINIMALLY INVASIVE radical hysterectomy for women with early-stage cervical cancer has been associated with reduced rates of disease-free and overall survival in the phase III LACC randomized noninferiority trial comparing minimally invasive and open abdominal radical hysterectomy. The results...
New Report Demonstrates Cost of Blood Cancer Care
THE COSTS to treat blood cancer are higher than the costs to treat other cancers, and the costs incurred by a patient diagnosed with a blood cancer do not return to precancer levels, according to a Milliman study commissioned by The Leukemia & Lymphoma Society (LLS). The study—The Cost Burden...
Illustrating Genius
FOUR AND A HALF YEARS AGO, author Neil Canavan attended a scientific conference to learn what he could about the then-emerging field of immunotherapy for cancer. After a presentation by Zelig Eshhar, PhD, principal investigator in the Department of Immunology at the Weizmann Institute of Science...
Clinician Survey to Explore Direct-Acting Oral Anticoagulants vs Low–Molecular-Weight Heparin in Cancer-Related VTE
Injectable low–molecular-weight heparin has long been considered the standard of care for treatment of venous thromboembolism (VTE) in patients with cancer. However, low–molecular-weight heparin is costly and often disliked by patients due to injection-related discomfort and bruising....
Improving Palliative Care in Low-Resource Settings
In 2016, ASCO published an update to its Clinical Practice Guideline, “Integration of Palliative Care Into Standard Oncology Care,” which provides evidence-based recommendations for symptom management, clarification of treatment goals, support of coping and distress management, and coordination of...
New Data Reported From International Studies of Lung Cancer Treatment
At the European Society for Medical Oncology (ESMO) 2018 Congress, important studies were presented for every cancer type. Here, The ASCO Post offers some snapshots of lung cancer studies that may inform approaches to treating this common cancer, which—despite the advances in recent years—remains...
FDA Approves Trastuzumab-pkrb for HER2-Overexpressing Breast Cancer
On December 14, the U.S. Food and Drug Administration (FDA) approved trastuzumab-pkrb (Herzuma), a HER2/neu receptor antagonist biosimilar to trastuzumab (Herceptin), for the following indications: Adjuvant breast cancer of HER2-overexpressing, node-positive or node-negative (estrogen...
FDA Approves Calaspargase Pegol-mknl for Pediatric and Young Adult Patients With ALL
On December 20, 2018, the U.S. Food and Drug Administration (FDA) approved calaspargase pegol-mknl (Asparlas), an asparagine-specific enzyme, as a component of a multiagent chemotherapeutic regimen for acute lymphoblastic leukemia (ALL) in pediatric and young adult patients aged 1 month to...
Statement From FDA Commissioner on In Vitro Companion Diagnostics
FDA Commissioner Scott Gottlieb, MD, recently issued the following statement on developing and class labeling of in vitro companion diagnostics for classes of oncology therapeutic products: “With a new draft guidance document that the FDA issued … our aim is to make it easier to get class labeling ...
Priority Review for Atezolizumab in Combination With Chemotherapy for Small Cell Lung Cancer
The U.S. Food and Drug Administration (FDA) accepted a supplemental biologics license application (sBLA) and granted Priority Review for atezolizumab (Tecentriq) in combination with carboplatin and etoposide for the first-line treatment of patients with extensive-stage small cell lung cancer. The...
Should I Have Lied?
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
International Trials Present New Findings in Treatment of Breast Cancer
The European Society for Medical Oncology (ESMO) 2018 Congress featured an assortment of study findings, many with far-reaching clinical implications for the treatment of patients with various cancers. Many of these trials were covered in-depth in recent issues of The ASCO Post. Here, we present...
Overscreening for Prostate Cancer in Older Men Remains an Issue
Although most major cancer organizations agree on the guidelines for prostate cancer screening, there is still uneven application of the test, such as in the older patient population, resulting in overdiagnosis and waste in an already fiscally challenged health-care system. Researchers from the...
Researchers at The University of Texas at Dallas Receive Funding for Assorted Cancer Projects
MORE THAN $4.5 million in new funding from state and federal agencies will support cancer-related research over the next 5 years at The University of Texas at Dallas. Two projects related to brain cancer, each totaling $200,000 over 2 years, recently received High-Impact/High-Risk Research...
Update on Immune Checkpoint Inhibitors
Checkpoint inhibitors have moved the field of immuno-oncology to the forefront of cancer treatment and research. However, these agents come with the risk of serious adverse events. To shed light on the toxicities associated with checkpoint inhibitors and other timely issues in the field of...
New NCCN Member Institution: Abramson Cancer Center of the University of Pennsylvania
In November, the National Comprehensive Cancer Network® (NCCN) announced that Abramson Cancer Center (ACC) of the University of Pennsylvania will become the organization’s 28th Member Institution. The Abramson Cancer Center’s membership will include the Hospital of the University of Pennsylvania...
ESMO Immuno-Oncology 2018: Second-Line Nivolumab vs Chemotherapy in SCLC
Treatment with nivolumab (Opdivo) did not improve response rates or survival over standard chemotherapy in patients with metastatic small cell lung cancer (SCLC) who relapsed following first-line treatment, according to findings presented by Reck et al at the European Society for Medical...
AACR Remembers George H.W. Bush for Role in Cancer Research Support
The Board of Directors of the American Association for Cancer Research (AACR) released an announcement expressing sadness upon the passing of former President George H.W. Bush, on November 30 at the age of 94. Once elected, President Bush appointed Bernadine Healy, MD, in 1991 to lead the National ...
